Margaret van Meter, MD
Hematology & Oncology · Murray, UTNPI 1528231511
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $243 of the $272 with a category attached, or 89.3%. Seagen Inc. accounts for 76.9% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $243 and has fallen 95.1% since, to $12 in 2021. That places this record below the midpoint for hematology & oncology clinicians in UT, where the typical reported total is $2,350.
Across 5 payments — averaging $54.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seagen Inc.$209
- Novartis$34
- E.r. Squibb & Sons, L.L.C.$17
- Gilead$12
Across 10 payments — averaging $19,653 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$94K
- Merck$53K
- Roche Products Limited$49K
What the payments were for
- Food & beverage$24389%
- Education$2911%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Seagen Inc. | 2 | $209 |
| Novartis | 1 | $34 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Gilead | 1 | $12 |
How this compares
$272 in reported general payments places this provider in the 15th percentile of 77 hematology & oncology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VerzenioAbemaciclib | 11 | $164,722 |
| Anastrozole | 65 | $1,285 |
| Letrozole | 19 | $366 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Murray
- Mark LewisMurray$319K
- Victoria VardellMurray$4K
- Clarke LowMurray$4K
- Rachel HuMurray$2K
- Caroline NebhanMurray$488
- Douglas SborovSalt Lake City$473K
- Belisario ArangoOgden$374K
- Daniel CourielSalt Lake City$229K
- Shiven PatelSalt Lake City$223K
- Neeraj AgarwalSalt Lake City$159K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.